Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Regeneron Pharmaceuticals, Inc.. A complete text table follows the diagram.
Sanofi's global commercial engine turns Dupixent growth into profit-share revenue, while Regeneron manages the EYLEA HD transition, scales Libtayo and reinvests heavily in the next pipeline.
Swipe to explore
All Sankey flows are reported GAAP amounts. The $154.8M other-product node and $294.6M Bayer-and-other-collaboration node are arithmetic groupings of separately reported filing lines. Global partner product sales appear only as context and are not added to Regeneron's revenue.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| EYLEA HD & EYLEA in the U.S. | 1 | $942M | Retinal-disease franchise |
| Libtayo | 1 | $438M | Global cancer immunotherapy sales |
| Praluent, Evkeeza & emerging products | 1 | $155M | Four reported product lines |
| Sanofi collaboration | 1 | $1.6B | Primarily Dupixent profit share |
| Bayer & other collaborations | 1 | $295M | International EYLEA economics |
| Royalties, technology & other revenue | 1 | $171M | Reported other revenue |
| Product & collaboration revenue | 2 | $3.6B | 19.0% year-over-year growth |
| Manufacture Regeneron-sold medicines | 3 | $373M | Reported cost of goods sold |
| Supply collaborators & contract customers | 3 | $296M | Reported collaboration manufacturing cost |
| Fund the internal pipeline | 3 | $1.5B | 42.8% of revenue |
| Acquire in-process R&D | 3 | $102M | Reported acquired pipeline expense |
| Commercialize & administer the portfolio | 3 | $648M | Reported SG&A |
| Operating income | 3 | $643M | 17.8% operating margin |
| Investment income less interest | 3 | $188M | Reported net other income |
| Income before tax | 4 | $831M | Reported pretax result |
| Income tax | 5 | $104M | Reported provision |
| Net income | 5 | $727M | $6.75 per diluted share |
| From | To | Value |
|---|---|---|
| EYLEA HD & EYLEA in the U.S. | Product & collaboration revenue | $942M |
| Libtayo | Product & collaboration revenue | $438M |
| Praluent, Evkeeza & emerging products | Product & collaboration revenue | $155M |
| Sanofi collaboration | Product & collaboration revenue | $1.6B |
| Bayer & other collaborations | Product & collaboration revenue | $295M |
| Royalties, technology & other revenue | Product & collaboration revenue | $171M |
| Product & collaboration revenue | Manufacture Regeneron-sold medicines | $373M |
| Product & collaboration revenue | Supply collaborators & contract customers | $296M |
| Product & collaboration revenue | Fund the internal pipeline | $1.5B |
| Product & collaboration revenue | Acquire in-process R&D | $102M |
| Product & collaboration revenue | Commercialize & administer the portfolio | $648M |
| Product & collaboration revenue | Operating income | $643M |
| Operating income | Income before tax | $643M |
| Investment income less interest | Income before tax | $188M |
| Income before tax | Income tax | $104M |
| Income before tax | Net income | $727M |